routine use in replete patients has limited evidence
no melanoma events in over 1,000 treated patients across surveillance periods No serious drug-related events : No consistent serious adverse events attributed to afamelanotide in pivotal trials Melanotan-2 Safety Profile# Melanotan-2 carries substantially more safety concerns: Common effects : Nausea in approximately 38% of injections (severe in approximately 15%)
Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, Paik JM
In many cases, starting with 250mcg per day is enough to stimulate healing without overstimulating pathways or triggering unwanted reactions
Combining AHK-Cu with other evidence-based approaches often produces better results than any single intervention alone
These optimistic clinical outcomes were validated in individuals with concurrent IBS-D, stress, and depression by a randomized controlled study (RCT) (262)